Saturday 17 October 2026
Export IMUX’s income statement to Excel — free account
Immunic, Inc.
IMUX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 60.0% and free cash flow fell 26.8%, each against the same quarter a year earlier.
6.97
0.13
−1.83%
Follow IMUX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
11.22 | 5.65 | 6.94 | 4.56 | 15.93 | 9.21 | 9.62 | 2.12 | 1.77 | 0.75 |
Net Debt/EBITDA |
1.52 | 1.10 | 1.09 | 0.79 | 2.60 | 0.95 | 1.35 | 0.47 | 0.36 | 0.15 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.87 | 0.78 | 0.84 | 0.82 | 1.05 | 0.90 | 0.54 | 0.76 | 0.84 | 0.88 |
Capex/Depreciation |
(0.31) | (0.68) | (2.13) | 49.20 | (3.74) | (0.79) | 0.00 | (3.01) | (1.97) | (0.96) |
| (58.21%) | (96.01%) | (94.98%) | (214.17%) | (40.54%) | (65.02%) | (100.01%) | (131.28%) | (424.44%) | (1,653.15%) | |
| (53.52%) | (83.72%) | (31.30%) | (88.07%) | (37.65%) | (60.56%) | (90.24%) | (102.84%) | (211.22%) | (299.36%) | |
ROIC |
0.00% | 0.00% | 0.00% | (79.83%) | (97.68%) | (142.33%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(70.05%) | (104.17%) | (100.79%) | (138.41%) | (35.06%) | (99.15%) | (106.48%) | (331.12%) | (567.77%) | 1,360.76% |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.50 | 0.20 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(462.78) | (412.40) | (115.35) | (33.78) | (29.54) | (35.22) | (20.51) | (16.06) | (8.49) | (5.52) |
Cash per Share |
764.22 | 571.30 | 154.33 | 38.03 | 81.37 | 36.72 | 36.57 | 10.53 | 3.56 | 0.99 |
Shareholders Equity per Share |
744.54 | 502.45 | 135.19 | 75.58 | 101.37 | 53.74 | 35.73 | 6.53 | 1.84 | (0.43) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
744.54 | 502.45 | 135.19 | 75.58 | 101.37 | 53.74 | 35.73 | 6.53 | 1.84 | (0.43) |
Free Cash Flow |
(36.33) | (41.07) | (9.77) | (26.08) | (46.27) | (83.30) | (65.26) | (71.16) | (85.03) | (85.97) |
Working Capital |
55.98 | 47.84 | 11.41 | 25.16 | 125.35 | 93.59 | 112.79 | 27.81 | 17.16 | (7.75) |
Capital Expenditures |
(0.55) | (0.68) | (0.03) | 2.46 | (0.15) | (0.07) | (0.11) | (0.33) | (0.26) | (0.16) |
Net Current Asset Value |
55.88 | 47.78 | 11.41 | 24.64 | 124.67 | 93.00 | 111.80 | 27.17 | 16.89 | (7.86) |
| Other line items | ||||||||||
Quick Ratio |
10.95 | 5.53 | 6.81 | 4.15 | 15.18 | 7.62 | 8.90 | 1.89 | 1.61 | 0.51 |
Depreciation/Fixed assets |
0.72 | 0.46 | 0.38 | 0.63 | 0.19 | 0.56 | 112.40 | 0.24 | 0.25 | 0.28 |
Cash ROIC |
(30.67%) | (38.41%) | (39.84%) | (29.73%) | (16.16%) | (38.93%) | (28.37%) | (94.12%) | (157.18%) | (975.79%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(455.72) | (405.59) | (114.97) | (36.97) | (29.45) | (35.19) | (20.47) | (15.98) | (8.46) | (5.51) |
Capex per Share |
(7.06) | (6.81) | (0.38) | 3.19 | (0.09) | (0.03) | (0.04) | (0.08) | (0.03) | (0.01) |
Average Receivables |
— | — | 0.30 | 0.30 | 0.35 | 0.29 | 0.29 | — | — | — |
Average Payables |
1.00 | 0.91 | 1.22 | 1.91 | 3.06 | 3.72 | 4.01 | 4.69 | 6.47 | 8.99 |
Average Assets |
76.55 | 62.21 | 36.88 | 39.66 | 116.91 | 153.48 | 133.43 | 91.03 | 47.58 | 32.46 |
Average Common Equity |
70.39 | 54.25 | 12.15 | 16.31 | 108.57 | 142.95 | 120.40 | 71.31 | 23.68 | 5.88 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates